Brief Title
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Official Title
A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Brief Summary
Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced
ovarian, fallopian tube or primary peritoneal cancer.
Detailed Description
The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response
after 2nd to 5th line of chemotherapy in patients with epithelial ovarian or fallopian tube
or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in
a previous line, while the response to the most recent Pt-based chemotherapy must not have
lasted more than 12 months. In addition the response between most recent 2 lines of
chemotherapy prior start of study medication must not have lasted more than 12 months.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Progression free survival
Secondary Outcome
To assess the safety and tolerability of maintenance therapy with single-agent PankoMab-GEX™ compared to placebo in patients with metastatic or recurrent ovarian or fallopian tube carcinoma or primary peritoneal carcinoma.
Condition
Ovarian Epithelial Cancer Recurrent
Intervention
PankoMab-GEX
Study Arms / Comparison Groups
PankoMab-GEX
Description: 1700mg, i.v., q3w
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
216
Start Date
September 2013
Completion Date
July 28, 2017
Primary Completion Date
April 20, 2017
Eligibility Criteria
Inclusion Criteria:
1. Female patients ≥18 years of age
2. Histologically-confirmed, TA-MUC1-positive, recurrent epithelial ovarian, or
fallopian-tube cancer or primary peritoneal cancer with high-grade (Grade 2 or 3)
serous features or a serous component
3. Availability of tumor tissue samples (slices or block) for immune-histological
confirmation of TA-MUC1 status (tissue samples could also be stored for other further
specified biomarker assessments)
4. Patients were to have received at least 2 lines but not more than 5 lines of
chemotherapy prior to start of maintenance treatment; neo-adjuvant lines did not count
as previous lines of treatment
5. Patients had to have a documented response to or SD following the most recent line of
chemotherapy (any regimen and duration in accordance with local or international
guidelines or within IEC-approved studies) and received the last dose of said
chemotherapy ≤6 weeks prior to randomization (response to prior chemotherapy was
defined as a PR/CR according to radiological response criteria and/or a confirmed
decline in tumor marker CA125 ≥50% from the pre-treatment value for patients who had a
pre-treatment value ≥2 x the upper limit of normal [ULN]; SD was defined as stable
disease according to radiological response criteria with a confirmed lack of increase
in tumor marker CA125 from the pre-treatment value for patients who had a
pre-treatment value ≥2 × ULN and no clinical progression). Prior to randomization,
CA125 had to be below the ULN, or CA125 levels were not to increase >15% within a time
frame >7 days if above the ULN
6. Progression-free interval of ≤12 months immediately preceding the chemotherapy to
which the patient had just responded
7. Sensitive or resistant to the most recent platinum-based chemotherapy preceding the
chemotherapy to which the patient had just responded (sensitivity was thereby defined
as a recurrence of disease >6 to ≤12 months after the end of platinum-based
chemotherapy, and resistantance was defined as a recurrence of disease ≤6 months after
the end of the platinum-based chemotherapy)
8. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
9. Recovered from all chemotherapy-related toxicities to Grade 1 or Grade 0 according to
the NCI-CTCAE Version 4.0, with the exception of alopecia (any grade) and peripheral
neuropathy (≤Grade 2)
10. Adequate bone marrow and hepatic function at Screening:
- Hemoglobin ≥9 g/dL
- White blood cell count ≥3.0 × 109/L
- Absolute neutrophil count ≥1.5 × 109/L- Platelet count ≥100 × 109/L
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × ULN (<5
× ULN in case of liver metastases)
- Bilirubin <1.5 × ULN (<3 × ULN in case of liver metastases)
- Creatinine <1.5 × ULN
11. Any patient with childbearing potential (i.e. not surgically sterile or
post-menopausal for >1 year) had to use highly effective contraceptives with a Pearl
index <1% according to the "Note for guidance on non-clinical safety studies for the
conduct of human clinical trials and marketing authorization for pharmaceuticals"
(CPMP/ICH/286/95) of the European Medicines Agency (EMA). (Although pregnancy was
unlikely to occur in this patient population, any patient with childbearing potential
had to be withdrawn from the study in the event of pregnancy)
12. Life expectancy >3 months
13. Ability and willingness to give written informed consent
Exclusion criteria:
1. Refractory to platinum-based chemotherapy (defined as remained progressive or became
progressive under any previous platinum-based regimen)
2. Progression-free interval of >12 months after the most recent antecedent
platinum-based chemotherapy regimen
3. Concomitant anti-tumor therapy or immunotherapy
4. Treatment with monoclonal antibodies or investigational agents ≤30 days before
randomization (prior anti-MUC1 therapy was not permitted at any time)
5. Limited-field radiotherapy ≤30 days before randomization (extensive prior radiotherapy
during or following the last line of chemotherapy was not permitted; radiotherapy
prior to the last line of chemotherapy was permitted)
6. Prior allergic reaction to a monoclonal antibody, Grade 3 IRR or any Grade 4 reaction
to a monoclonal antibody
7. Known sensitivity to any component of the test product
8. Contraindication to the pre-medication used in this study (paracetamol/acetaminophen,
H1 and/or H2 receptor antagonists, or steroids)
9. Clinical evidence of brain metastasis or leptomeningeal involvement
10. Patients with second primary cancer, except adequately treated non-melanoma skin
cancer, curatively treated in-situ cancer of the cervix, ductal carcinoma in situ,
Stage 1 Grade 1 endometrial carcinoma, or other solid tumors including lymphomas
(without bone marrow involvement) curatively treated with no evidence of disease for
≥5 years
11. Primary or secondary immune deficiency
12. Clinically active infections >Grade 2 using NCI-CTCAE version 4.0
13. Active hepatitis B or C or infection with human immunodeficiency virus (HIV)
14. Myocardial infarction within 6 months prior to Screening
15. Symptomatic congestive heart failure (New York Heart Association Grade 3 or 4),
unstable angina pectoris within 6 months prior to Screening, significant cardiac
arrhythmia or history of stroke or transient ischemic attack within 1 year prior to
Screening
16. Prior or planned major surgery within 30 days prior to randomization and/or incomplete
recovery from prior surgery
17. Concomitant use of systemic steroids, except for inhaled, topical or nasal application
within 30 days prior to randomization (steroids used for pre-medication were
permitted)
18. Active drug or alcohol abuse
19. Any uncontrolled medical condition that could have put the patient at high risk during
treatment with an investigational drug, including unstable diabetes mellitus, vena
cava syndrome, or chronic symptomatic respiratory disease
20. Pregnancy or lactation
21. Legal incompetence, limited legal competence, or detainment in an institution for
official or legal reasons
22. Receipt of any other investigational medicinal product within the last 30 days before
randomization or any previous PankoMab-GEX™ administration
Gender
Female
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Jonathan Ledermann, MD, ,
Location Countries
Germany
Location Countries
Germany
Administrative Informations
NCT ID
NCT01899599
Organization ID
GEXMab25201
Secondary IDs
2013-000931-28
Responsible Party
Sponsor
Study Sponsor
Glycotope GmbH
Study Sponsor
Jonathan Ledermann, MD, Principal Investigator, UCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK
Verification Date
October 2020